Osteopore (ASX:OSX) Secures A$2.6M China Deal: Micro-Cap Opportunity or Too Risky to Buy?

Osteopore signs a major China distribution deal, but risks remain

Osteopore (ASX: OSX) surged 71 per cent last Friday after announcing an exclusive distribution deal with Majeton Limited valued at above RMB 12 million (approximately A$2.6 million). The agreement covers China, Hong Kong, and Macau. For a company with a market capitalisation of just A$2.4 million, this deal is huge; it represents more than the company’s entire market value in contracted revenue. The partnership gives Osteopore access to one of the world’s largest healthcare markets, but can this tiny company actually deliver?

What are the Best ASX Healthcare Stocks to invest in right now?

Check our buy/sell tips

What Osteopore Actually Makes

Osteopore makes 3D-printed implants that doctors use in bone surgeries, particularly for the skull, face, and jaw. What makes these implants special is that they dissolve naturally over time as the patient’s own bone grows back. This means patients do not need a second surgery to remove the implant later.

Think of it like a scaffold that holds everything in place while the bone heals, then slowly disappears once the job is done. The technology has been used in more than 30,000 surgeries worldwide, which shows that it works. However, the company remains very small and has struggled to turn this technology into meaningful profits so far.

China Entry Via Essex Bio-Technology Network

The real value of this deal lies in who Osteopore is partnering with. Majeton is connected to Essex Bio-Technology, a company listed in Hong Kong with strong relationships across Chinese hospitals. This gives Osteopore immediate access to doctors and healthcare facilities that would normally take years and millions of dollars to build on its own.

Majeton will handle sales, marketing, and distribution across China, Hong Kong, and Macau. This means Osteopore does not need to spend heavily on building its own sales team in the region. The partnership allows the company to focus on making the product while Majeton focuses on selling it.

However, there is an important catch. Osteopore still needs Chinese regulatory approval before it can actually sell products there. This approval process can be slow and unpredictable. Until that happens, the revenue remains a promise rather than a reality.

The Investor’s Takeaway

Osteopore closed last week at A$0.012 per share after its 71 per cent surge, up from a previous close of A$0.007. The stock remains well below its 52-week highs, but this deal has clearly caught the market’s attention.

We believe this remains an ultra-high-risk opportunity. The A$2.6 million deal is genuinely significant for a company this size, but several concerns remain. First, the company’s quarterly revenue sits at just A$812,000, showing the business is still very small. Second, regulatory approval in China is not guaranteed and could take considerable time. Third, with such a tiny market cap, the shares are thinly traded, which means buying or selling large amounts could move the price significantly.

For speculators who accept that they could lose their entire investment, Osteopore offers a big upside if everything goes right in China. The technology is proven, the partner appears credible, and the deal size is meaningful. But for most investors, the safer approach is to wait for evidence that Chinese sales are actually happening before committing capital. This is a punt, not an investment.